As of Jul 22
| 0.00 / 0.00%|
The 8 analysts offering 12-month price forecasts for Celldex Therapeutics Inc have a median target of 6.50, with a high estimate of 24.00 and a low estimate of 3.00. The median estimate represents a +37.13% increase from the last price of 4.74.
The current consensus among 9 polled investment analysts is to Buy stock in Celldex Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.